SRP 9003 for the treatment of limb-girdle muscular dystrophy type 2E shows sustained expression and functional improvements 2 years after administration.- Sarepta
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest